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so important for our livings here. 
 
    There are also a lot of anonymous acknowledgement should be mentioned here. For all 
of those who helped us I just want to say: “thank you very much!” 
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Summary 
 
   With the coming prospect of genetic testing a lot of problems will arise. In the health 
insurance market there are concerns that the insurers will misuse the genetic information for 
risk classification and the problem of genetic discrimination will come out. Many countries 
have made policies to limit the  insurers to get access to genetic information.  
 
    But there is another problem that the consumers on the other hand have the freedom to 
choose to be tested or not. They will judge whether it is valuable for them to accept the test 
and whether to reveal the testing results to the insurers. It is about the value of genetic 
information. 
 
     In this thesis I pay special attention to the private value of genetic information. That is, 
the ex ante value of genetic information to the individuals and their choice to be tested or 
not. I think it is of primary importance because if the individuals do not accept the testing, 
then there is no significance of setting policies limiting the insurers to use it for underwriting 
purposes. 
 
    In the introduction I give some concepts clarification such as adverse selection, risk 
classification and genetic testing. Then I make literature review as to the researches done in 
this field. Third I introduce the structure of this thesis. 
 
  The main body of this paper is devoted to the private value of genetic information. The 
analysis is extended from three perspectives: public/private information; prevention 
unavailable/available; information cost zero/positive. But the third point is just touched but 
not analyzed adequately because of the unavailability of enough information on this point. 
 
     In section 2 the situation of public information is analyzed. First a case of no 
prevention and costless information is given as a benchmark for further analysis. The result 
is that for risk-averse individuals the value of genetic information is negative and they would 
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remain uninformed and accept the uniform contract for all people. Secondly the prevention 
is taken into consideration and still with the assumption of costless information. A simple 
model is given for the value of information with insurance coverage and prevention cost as 
variables. Then the conclusion is that the value of genetic information is ambiguous with the 
prevention available. It depends on the comparison of positive value of prevention and 
negative value of risk classification. If the latter has greater influence then the value will be 
negative. Otherwise the value will be positive. 
 
    In section 3 the situation of private information is considered. Firstly it is still assumed 
that the prevention is not available. Much has been drawn upon the paper written by Doherty 
and Thistle (1996) as background for my analysis. Then with the price-quantity mechanism 
and self-selection constraints as tools for analysis, several circumstances are considered one 
by one. First, it is assumed that the risk type is private information but the information status 
of the individuals is  known to the insurer. Then it is shown that the value of genetic 
information is negative. Second, it is assumed that informational status is private information 
as well as risk types. In this case, the value of genetic information is non-negative. Third, it 
is assumed that the consumers can choose to reveal negative results and conceal positive 
results. Then the value of information is positive. In the end, the effect of positive 
information cost was considered. Secondly it is assumed that the prevention is available. For 
simplicity the prevention cost is set to be a fixed number. And it is assumed that the 
prevention is socially efficient for the high-risk individuals. Two circumstances are 
considered. First, the informational status is private information. Then it was derived that the 
value of information is positive. Second, the individuals can choose to reveal good risks and 
conceal bad risks. In this situation the value of information is also derived to be positive. 
 
    In section 4 the social efficiency aspect of the genetic information is investigated. But 
there is no formal analysis. Some of the conclusions given by other researchers are 
introduced here. After that some policies are introduced and some suggestions on the avert 
of adverse selection after genetic testing are given. 
 
    In the last section 5 some concluding remarks are given. 
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1. Introduction 
1.1 Some concepts closely related to the problem  
1.1.1 Adverse selection in health insurance market 
 
  The problem of adverse selection will arise if the population is heterogeneous in terms of 
the risk to be insured and asymmetry of information is present. Here, asymmetry of 
information means that the individual knows his risk whereas the insurance company cannot 
observe it. Therefore, the company is constrained to offer insurance on equal terms to 
everyone. 
 
    The impact of asymmetric information on the working of markets was first expounded by 
Akerlof (1970) in his essay “ the Market for Lemons”. The quintessence of this famous 
essay is that an information advantage of the seller over the buyer of a good with non-
uniform quality causes bad quality to chase good quality from the market. This is called 
“adverse selection”. The same problem occurs in health insurance market. 
 
Assume that the population is heterogeneous in terms of the risk of becoming ill jπ  as 
well as in terms of the cost of treatment in case of illness jL , and every individual j  knows 
his pair of values. The insurer, however, lacks discriminatory power to assign the 
appropriate values of risk parameters to applicants. He will therefore only offer a standard 
policy, which is characterized, for example, by a partial payment of claims in case of illness, 
)10( << rr  and by a premium P . The value of r  and P  must be set such that expected 
payments for claims of the insurance company are at least covered by the premium. Assume 
that there is no cost of administration and perfect competition of the insurance market, then 
the risk neutral profit maximizing insurance company will get zero profit. This assumption 
will hold throughout the paper. 
 
Let us presume that the insurance company only writes an insurance contract with full 
coverage ( 1=r ), which it believes to be sold to a representative sample of the population. 
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This means that the premium P  is calculated on the basis of expected values of π and L . 
Such a policy will be attractive to all “bad risks”, which are those individuals with a high 
value of jπ  and jL , and, given risk aversion, also for average risks. In contrast, very good 
risks, that is, individuals with values of jπ  and jL  well below average, will avoid buying 
such a policy (unless they are extremely risk averse). The reason is that the ratio between 
premium and expected costs of illness is very unfavorable to them. On the other hand, 
because of the reasons mentioned (lack of discriminatory power on the part of the insurance 
company), a more favorable premium cannot be offered to this group because all other 
insureds would also demand these better terms. 
 
Since the best risks drop out, the basis upon which the insurance company calculated its 
risk premium changes, causing the premium to rise. Thus the offered policy becomes 
unattractive for another group of individuals with relatively low values of jπ  and jL , who 
drop out in their turn, so that the premium required to cover costs rise even more. This 
process, called adverse selection, continues until in equilibrium, only the worst risks remain 
in the insurance pool. 
 
In this situation, a separating equilibrium policy set may exist as stated by Rothschild and 
Stiglitz (1976). They showed that in an insurance market with imperfect information, the 
seller specifies both the prices and quantities of insurance purchased. In most competitive 
markets, sellers determine only price and have no control over the amount their customers 
buy. They define equilibrium in a competitive insurance market as a set of contracts such 
that, when customers choose contracts to maximize expected utility. 1) No contract in the 
equilibrium set makes negative expected profits. And 2) there is no contract outside the 
equilibrium set that, if offered, will make a non-negative profit. Then at equilibrium, the 
high-risk individuals exert a negative externality on the low-risk individuals. The low risks 
can not get full coverage at actuarially fair rate. But the high-risk individuals are no better 
off from the losses of the low-risk individuals. We will exert this result later in out analysis. 
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1.1.2 Risk classification of insurance company 
 
    Adverse selection is technically defined as the tendency of persons with knowledge of 
their poorer than average health expectations to apply for or renew insurance to a greater 
extent than persons with average health risks. Concerns about adverse selection are two-
folded: 1. Low-risk insureds will unfairly subsidize high-risk insureds and 2. Through 
inadequate rates and large insurance purchases by high-risk individuals, the insurers’ 
financial solvency is jeopardized. By collecting medical information about its applicants, 
insurers can avoid losses from applicants who have undergone medical testing and withheld 
testing results. “Risk classification”, in turn, is a process by which an individual’s premium 
may be determined. The goal of risk classification is to determine the applicant’s expected 
losses and to place insureds with similar expected losses into the same class so that each may 
be charged the same rate. The most important underwriting factors used to classify insureds 
are age, current health status and future health status. Current health status is assessed from 
the application, physical examination and medical testing. The traditional medical testing 
required by insurers include routine biochemical tests, urinalyses, electrocardiograms and x-
rays. Future health status typically is predicted on the basis of current or past health 
conditions and the potential for exacerbation or recurrence. The coming prospect of genetic 
testing undoubtedly will dramatically increase the risk classification power of the insurers. 
 
1.1.3 Genetic testing 
 
On June 26th, 2000, the leaders of both the privately and the publicly funded human 
genome projects announced that a draft of the human genome has been made. During the 
next few years, this knowledge is likely to be applied in the development of predictive tests 
for many diseases. The test will be able to distinguish between high- and low- risk 
individuals at a pre-symptomatic stage of disease. Presently, tests for over 800 diseases are 
offered, including tests for Huntington’s disease and cystic fibrosis. Two important breast 
cancer genes have been identified, and the US Food and Drug Administration has approved 
a gene-based test that may help to predict the recurrence of breast cancer. The number of 
tests is expected to increase rapidly in a few years, in parallel to the mapping of the human 
genes. For instance, tests for genes that imply an elevated risk of several types of cancer, 
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cardiovascular disease, and Alzheimer’s disease are already available or are expected to be 
available in the near future. 
 
 The information from gene-based tests may be of various values. First, it may be used to 
initiating measures for postponement and prevention of disease. Second, it has an impact on 
health insurance. There is a concern that insurers can make use of information to deny 
coverage or require prohibitively high premium for individuals with an increased risk of 
disease. Many countries have approved restrictive laws for insurers to get access to 
information out of genetic testing. For instance, the Council of Europe, recommends (R(92)3 
and R(97)5) that predictive genetic tests should not be used when the terms of insurance is 
decided. In the US, a majority of the states have banned the use of genetic information by 
insurers. Although there are different voices declaring that genetic information should be 
available to insurers, the main theme is prevention of insurers from getting access to 
information generated from genetic testing. 
  
   
1.2 Literature review 
 
    But with the enforcement of those restrictive laws concerning insurer’s access to genetic 
information, a lot of problems will arise: would the individual like to take a genetic test and 
know his genetic mutation indicating increased likelihood to develop a particular disease? If 
this information is private that only the individual knows and the insurer doesn’t know, will 
there be the problem of adverse selection? What’s the private and social value of genetic 
information? When taken into consideration the prevention possibility (of course with cost) 
and information with cost, will the individual like to be tested? How to avert the problem of 
adverse selection coming out of the endogenous information? 
 
 Much research has been done on the impact of genetic testing on health insurance market 
ever since 1980’s. And a lot of literature can be found on this problem. Among them there 
are some needed to be reviewed before the formal discussion of this paper. 
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 Studies by Crocker and Snow(1986), Dahlby(1983), Hoy(1982, 1984) and 
Schmalensee(1984) have analyzed the economic effect of categorical discrimination in 
insurance markets when information is asymmetric. These models characterize heterogeneity 
among individuals by assuming that insureds possess exogenous specified loss probabilities 
that vary according to risk type. The individuals are assumed to possess perfect and private 
information regarding their risk type. These studies show that there may be both beneficial 
efficiency effects and adverse distribution effects resulting from categorization. Distribution 
effects are caused directly by the use of risk class prices while efficiency improvements may 
arise as a result of the elimination or mitigation of the adverse selection problem. 
 
Michael Hoy published an article “ the Value of Screening Mechanism under Alternative 
Insurance Possibilities” in 1989. He investigated the welfare implications of symmetrical 
improvements in information and accompanying screening mechanism which allow for 
improved matching of individuals to their respective risk classes. He assumed that the 
individuals differ not only according to exogenous specified loss probabilities, but also 
according to self-protection technologies. He ruled out the problem of adverse selection by 
assuming that risk class information is provided symmetrically to both insureds and insurers. 
Nonetheless, he still demonstrated that improvements in such information affect both 
efficiency and distribution as for the case when adverse selection does persist. He showed 
that efficiency effect may occur either directly as a result of better knowledge concerning the 
relative effectiveness of self-protection across risk types or indirectly through the incentives 
created by effects of information on market prices for insurance. 
 
Tabarrok(1994) also gave some idea concerning the benefits and costs of genetic testing. 
The greatest benefit of testing occurs when a deterministic disease with highly effective 
therapies is detected. The collection of data on genetic defects, when correlated with 
environmental and other factors, can lead to improved therapies. He suggested that the costs 
of genetic testing fall into two categories, the actual cost of the tests (social cost) and the 
distribution cost (private cost). He assumed that the social benefits exceed the social cost of 
the tests. And then the more important is the distribution cost or private cost. But he didn’t 
give deep analysis of this problem. However, he gave an important proposal about genetic 
insurance. We are used to thinking of insuring against sickness but here he suggested 
insuring against a potential high probability of sickness. Before taking a genetic test, it 
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should be made mandatory for every individual to purchase genetic insurance. For a small 
fee genetic insurance would insure against the possibility of a positive test result. If the test 
came back positive the customer would be paid a large sum of money, enough to cover the 
expected costs of his disease or equivalently enough to allow him to purchase health 
insurance at the new risk premium. If the test turns out negative the customer would lose his 
genetic insurance fee but would gain the results of the test and also lower health insurance 
premium. This proposal require some legislation, enforcement on buying genetic insurance 
before taking the test but it avoids the problem of adverse selection. So it has drawn great 
attention and been approved by many researchers since the concept been brought out. 
 
Doherty and Thistle(1996) contributed a lot to the analysis of adverse selection with 
endogenous information in insurance market. Traditional models of adverse selection always 
assume that the risk types are known to the consumers but not to the insurer. Doherty and 
Thistle considered the risk information to be endogenous and the incentive for the individual 
to gather information. They showed that the private value of information is non-negative 
only if insurers cannot observe consumer’s information status, or if consumers can conceal 
their information status. They also showed that the positive value of information does not 
depend on consumer’s initial information; rather, it is a consequence of the non-
observability of information status. Policy-holders’ information value must be positive for 
them to have an incentive to learn their risk type, and for adverse selection to arise 
endogenously. But they didn’t consider the possibility of prevention and their analysis apply 
to general test instead of genetic test. The difference between the two kinds of tests is that 
general test is always required by the insurance company before issuing the insurance policy 
and the genetic test maybe forbidden to be required by the insurance company. 
 
  In a newly published paper, Hoel and Iversen(2000) analyzed two types of social 
inefficiencies occurring when information about prevention and test status is private. Their 
analysis is based on the assumption that prevention is available to reduce the risk of disease 
for the high-risk individuals and there is mix of compulsory and voluntary insurance. The 
two types of inefficiencies are: genetic testing may not be done when it is socially efficient 
and may be done when it is socially inefficient. The first type of inefficiency is shown to be 
likely for consumers with compulsory insurance only while the second type of inefficiency 
is more likely for those who have supplemented the compulsory insurance with substantial 
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voluntary insurance. And the second type of inefficiency is more important the less effective 
prevention is. They assumed costless information but in reality, genetic testing will not be 
too cheap to be available easily. It brings the individual an expected cost when considering 
accepting a genetic testing. 
 
 
1.3 The structure of this thesis 
 
  With the coming prospect of genetic testing being used for diagnostic purposes, many 
problems will arise. Will it be of positive or negative value for each individual being tested? 
Should the insurers and employers use the information for risk classification and promotion? 
If so, will there be unfair genetic discrimination? How can economic theory shed light on 
such problems? Is there anything the policy makers can do to balance the interests of 
different agents? 
 
Of the various questions, I am particularly interested in the private value of genetic 
information for those considering accepting a test because any advancement in technology 
should bring benefits to the general individuals. If it is of no value or even negative value, 
there will be a waste to invest on the development of such technology. If the genetic 
information has positive value for the individuals, they will be likely to take a test and make 
use of prevention if revealed to be high risk. This is of great significance to not only the 
individual himself but also to his family and other people related. If the genetic information 
has negative value for the individual, he will not choose to be tested and remain uninformed 
even if he is of high-risk group. Hence, a timely prevention may be delayed and harmful 
consequences may come out. 
 
 So the main body of this paper will be devoted to the private value of genetic 
information. The analysis is extended from three perspectives: public/private information; 
prevention unavailable/available; information cost zero/positive. But the third point is just 
touched but not analyzed adequately because of the unavailability of enough information on 
this point. 
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 In section 2 the situation of public information is analyzed. First a case of no prevention 
and costless information is given as a benchmark for further analysis. The result is that for 
risk-averse individuals the value of genetic information is negative and they would rather 
remain uninformed and accept the uniform contract for all people. Secondly the prevention 
is taken into consideration and still with the assumption of costless information. A simple 
model is given for the value of information with insurance coverage and prevention cost as 
variables. Then the conclusion is that the value of genetic information is ambiguous with the 
prevention available. It depends on the inter-act of the positive value of prevention and 
negative value of risk classification. If the latter has greater influence then the value will be 
negative. Otherwise the value will be positive. 
 
 In section 3 the situation of private information is considered. Firstly it is still assumed 
that the prevention is not available. Much has been drawn upon the paper written by Doherty 
and Thistle (1996) as background for my analysis. Then with the price-quantity mechanism 
and self-selection constraints as tools for analysis, several circumstances are considered one 
by one. First, it is assumed that the risk type is private information but the information status 
of the individuals is  known to the insurer. Then it is shown that the value of genetic 
information is negative and uninformed would choose to remain uninformed. Second, it is 
assumed that informational status is private information as well as risk types. In this case, 
the value of genetic information is non-negative. Third, it is assumed that the consumers can 
choose to reveal negative results and conceal positive results. Then the value of information 
is positive. In the end, the effect of positive information cost was considered. Secondly it is 
assumed that the prevention is available. And for simplicity the prevention cost is set to be a 
fixed number and the loss probability will be decreased to a proportion of the original 
amount. And it is assumed that the prevention is socially efficient for the high-risk 
individuals. As the analysis before, the self-selection mechanism is used here. Two 
circumstances are considered. First, the informational status is private information. Then it 
was derived that the value of information is positive. Second, the individuals can choose to 
reveal good risks and conceal bad risks. In this situation the value of information is also 
derived to be positive. Then this result is consistent with the result given by Hoel and 
Iversen (2002) and some of their analysis is introduced here. 
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 In section 4 the social efficiency aspect of the genetic information is investigated. But 
there is no formal analysis. Some of the conclusions given by other researchers are 
introduced here. After that some policies are introduced and some suggestions on the avert 
of adverse selection after genetic testing are given. 
 
 In the last section 5 some concluding remarks are given. 
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2. The situation of public information 
 
  In this section I will give a formal analysis of the value of genetic information in the 
situation of public information. I denote information as public if the insurer has access to as 
much information relevant for risk assessment of a potential policy holder as the policy holder 
has himself. The information includes the individual’s risk type, whether or not he has taken a 
genetic test, the test result, the prevention undergone by the high risk individual and its effect on 
the risk of getting ill, etc. So this is a very strong assumption and it’s not quite  realistic. But it 
will be a starting point for further analysis. 
 
First, I will give a simple model with the assumption that there is no prevention available to 
the individual. The information cost is set to be zero. Some basic assumptions concerning the 
individual and the insurer will be given here. Although the model is too simple, it will serve as a 
benchmark for further discussion. 
 
 Second, the prevention will be taken into consideration. Of course there is a cost for it. But 
the information is still assumed to be costless as above. In this part, a model will be given to 
reveal the value of genetic information. Then it will be shown that with prevention available, the 
value of genetic information is ambiguous under public information.  
 
2.1 No prevention is available. 
 
    And first information is assumed to be free, i.e., the information cost is zero. 
 
 Some basic assumptions: 
 
 1). There are two possible states of nature for every individual: the state of sickness ( s  for        
 short) and the state of good health (h  for short). 
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 2). There are two population H  and L  with different risk of sickness Hπ  and Lπ , with   
   0< Lπ < Hπ <1. 
 
 3). The proportion of the high risk group in the population is µ  and the proportion of the  
      low risk group is .1 µ−  
 
4). The good health state yields an income y and the sickness state entails a loss l . The loss  
    l  comes from treatment costs and loss of earnings. 
 
5). The individuals are risk averse. Their utility function is state independent and depends  
     only on the income in each state. The good health itself has a value but I ignore it here.  
     The utility function )(⋅u  is increasing and strictly concave that is 0)( >⋅′u  and .0)( <⋅′′u  
 
6). The parameters Hπ , Lπ and µ  are assumed to be common knowledge. 
 
7). Prior to the introduction of genetic testing, nobody knows his risk type. Hence, initially,  
     as uninformed, the whole population is assumed to have an identical perception of their  
     own risk equal to a weighted average of the actual risks of the two groups:  
     LHU πµµππ )1( −+= . 
 
8). The insurers are risk neutral and expected profit maximizing. They operate in a perfectly  
    competitive market with administration cost. So they earn zero expected profit. If 
someone  
    get positive profit, the competition of this market will drive the price of insurance down  
    and the profit will decrease to zero. 
 
9). The insurance contract is characterized by a pair of parameters ),( IP . P  is the premium  
     paid by the insured and I  the indemnity paid by the insurer when there is a claim from  
    the insured. 
I
P=σ  is the unit price of the insurance contract. 
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Some conclusions derived from the above assumptions: 
 
1) Because the insurer gets zero expected profit, the expected payment for claims will just 
be covered by the expected revenues from the premium. So  
 
              iiiiii II σπσπ )1()1( −=− , ⇒ ii πσ = ,  
 
     The insurance will be offered at actuarially fair rate. 
 
2) With the insurance purchase of the individual, the expected incomes in both states will  
     be: 
 
               ii
s
i IPlyy +−−= ii Ily )1( σ−+−= , 
              iii
h
i IyPyy σ−=−= .                            ),( LHi =  
 
And the expected utility will be 
 
            )()1()( hii
s
iii yuyuEu ⋅−+⋅= ππ  
 
The individual will maximize the expected utility with respect to the insurance coverage. 
 
   
)()1())1((
)()1()(max
iiiiii
h
ii
s
iiiI
IyuIlyu
yuyuEu
i
σπσπ
ππ
−⋅−+−+−⋅=
⋅−+⋅=
 
 
The first order condition to be satisfied is  
 
          0)()1()1()( =⋅′⋅−−−⋅′⋅=∂
∂
i
h
iiii
s
i
i
i yuyu
I
Eu σπσπ  
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 and because  
 
           ii πσ = ,  so )()( isih yuyu ′=′   
 
Then the marginal utilities in both states are equal. Because the utility function is 
increasing and concave, the expected income in both states are equal. This means full 
coverage for the risk-averse individual. The risk associated with treatment costs is 
completely covered by insurance. 
 
The simple model: 
 Due to the identical perception of the individuals on their risk type, a uniform insurance 
contract will be supplied to the population with the unit price =Uσ LHU πµµππ )1( −+=  
 
 If an individual decides to take a genetic testing, this will bring him before an 
information lottery. With probability µ  he will be revealed to be a high risk one and with 
probability µ−1  a low risk one. The expected income after the testing will be respectively 
Iyy HH π−=  and Iyy LL π−= .  
 
But if the individual does not take the test, he will be offered the uniform contract and the 
expected income is Iyy UU π−= . Since HUL πππ << , the expected incomes in three 
states are conversely HUL yyy >>  and the expected value of the information will be  
          )()()1()( ULH yuyuyuVI −⋅−+⋅= µµ  
 
 and because LHU yyy )1( µµ −+= , then for risk averse individual, the expected utility of the 
two incomes Hy , Ly  will be less than the utility of the expected income Uy . 
14 
 
 After comparing the utility of the information lottery and the utility of the state of 
ignorance, the ex ante private value of genetic information for the individual will be negative 
and he will choose not to be tested. The intuition of this result is obvious. Since abnormal 
genetic mutation indicating an increased likelihood of some disease is always rare compared 
with the normal mutation. A large proportion of the population belongs to the group of low 
risk. Illustrated by the figure 1, it is shown that Hy  is very small and Uy  near Ly . So the 
individual will be fined a lot by a much more expensive insurance contract offered to him if 
revealed to be a high risk one. On the other hand, he will get little by a little cheaper contract 
available if revealed to be a low risk one. A risk averse individual would rather pay a little 
more than the best contract than game to be fined a lot by taking the genetic testing and 
being revealed to be a high risk one. The uniform contract is so cheap that they ignore the 
price difference between the cheapest contract. 
 
figure 1: The utility for risk-averse individual 
 
 
LyHy
)(Eyu
)(yEu
Uy
)(yu
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When the information has a cost out of the personnel fee and equipment cost the private 
value of the information is even more negative. Because in addition to the risk classification 
cost to the individual, a fixed amount of money has to be paid before the test regardless of 
the test result. 
 
Proposition 1: In the circumstance of public information and no prevention available and 
regardless of the information cost zero or positive, the private value of genetic information is 
negative. The risk-averse individual will choose not to be tested and stay behind the veil of 
ignorance to maintain an average level of utility by purchasing a uniform insurance contract. 
 
2.2 Prevention is available for the high risk individual. 
 
In this situation, an individual in the group of high risk can choose a level of prevention 
measured by the prevention cost v  in utility terms and choose the insurance coverage to 
maximize the expected utility after prevention. Assume that the production function of the 
prevention is )(vHπ  and it has the following properties: 
 
 0,),( >LUH v πππ                                                                                                        ( a ) 
0)(,0)( >′′<′ vv HH ππ                                                                                                    ( b ) 
LH ππ >∞)(                                                                                                                   ( c ) 
LHU πµµππ )1()0( −+=                                                                                               ( d ) 
 
Property (c) means that the high-risk one can never be turned into a low-risk one just buy 
means of prevention. There is also an implicit assumption that only high-risk individuals will 
take prevention while the uninformed will not. 
 
Due to the symmetry of information in the health insurance market, actuarially fair 
insurance contracts will be offered to the applicants. The insurance available by the 
individual after prevention is at the price )(vHπ , and the utility to be maximized is  
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The first order conditions to be satisfied are as following: 
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u ππππ                          (1) 
 
And this condition lead to )()( hs yuyu ′=′ , because the utility function is increasing and 
concave the incomes in both states are equal hs yy = . It means full insurance coverage for 
the individual. The risk of treatment cost in case of sickness is fully covered by the insurance 
indemnity. 
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because hs yy = , the above condition can be transformed into  
 
               1)()( =′′− Ivyu Hs π                                                                                          (3) 
 
In equation (3) the marginal cost of prevention is 1 and equal to the marginal benefit, 
which consists of three components: firstly, the marginal reduction in the loss probability 
)(vHπ ′ . Secondly, this reduction leads to the saving of premium in absolute value as 
IvH )(π ′− . And thirdly, the saving of expenditure on premium measured in utility term: 
)( syu′ is the utility increase with a unit increase in income, )( syu′  times IvH )(π ′−  is the 
increase in utility from the premium reduction caused by a marginal increase in prevention.  
 
 Suppose the high-risk individual will choose an optimal level of prevention *v  to satisfy 
the above mentioned condition (3). 
 
17 
The individual will be offered the contract 
)( *vHC  if he is revealed to be a high risk one 
and take prevention at the level *v . If he remains uninformed, the uniform contract UC  is 
available for him. So the testing now presents an information lottery to him. With probability 
µ  he will be revealed to be a high risk one and to maximize the expected utility he will take 
prevention and with probability µ−1  he will be revealed to be a low risk one and be offered 
the contract LC  with the lowest insurance price. Assume that the expected utility received by 
a consumer with probability of loss π  under the insurance policy C is 
)()()1(),( IPlyuPyuCV +−−⋅+−⋅−= πππ . 
 
 The value of information in this circumstance is  
 
               { } ),(),()1())(,()( **
)( * uuLLHvH CuCuvvCuvVI ππµπµ −−+−=  
 
When 0* =v  this is the case discussed above: public information without prevention 
available and the result is that )0(VI  is negative. 
 
  When 0* >v , we can transform the value of information by adding and subtracting 
),( HHCu πµ ⋅  into the following form: 
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Now the value of genetic information can be separated into two parts: 
1) The value of the preventive option: with probability µ  the individual will be recognized 
as a high risk one. This brings him to the risk of buying an expensive contract at the unit 
price Hπ . But this also opens him to the possibility of prevention to reduce the risk of 
disease to )( *vHπ  by spending cost *v on prevention. When the prevention is of value 
(positively marginal productivity), this term is positive. 
 
2) The value of risk classification lottery: the decision to take the test exposes the 
individual to a lottery, either to turn out as a high risk one with probability µ  or as a low 
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risk one with probability µ−1  of getting ill. On the other hand, if uninformed, the 
individual has a policy offering full insurance coverage at a fair price Uπ . As discussed 
above, for a risk-averse individual, the lottery reduces expected utility which implies that 
the second term is negative. 
 
So we can summarize the conclusion as following:  
  The value of genetic information that is also known by the insurance company is 
ambiguous when there is a preventive option for high-risk individual. When the value of the 
preventive option exceeds the absolute value of the risk classification lottery, it is positive in 
all and the uninformed will choose to take a test and take prevention at optimal level if 
revealed to be high risk. This applies to the case of some diseases with effective prevention 
or treatment. But for the case without effective prevention, the value of information is 
negative. The risk-averse individual will choose not to be tested. 
 
  When the information is not free to get, the result is still ambiguous. Suppose that the 
information cost is r and 0>VI , if VIr > , the information cost is greater than its benefit; if 
0<VI , the information has still more negative value. And in the only case that rVI > , the 
value of information is positive and the uninformed will choose to be tested. 
 
Proposition2: in the situation of public information and prevention available, the value of 
genetic information is ambiguous. It is positive if the positive effect of prevention is greater 
than the negative effect of risk classification and negative if the prevention is not so effective 
to overcome the negative effect of risk classification. 
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3. The situation of private information 
3.1 No prevention available 
 
  As in the last section, there is a continual of consumers who are assumed to be identical 
in all easily observable respects. Each consumer has a fixed income y in state of good health 
and suffers a loss l  in state of illness. The disease is determined by an abnormal genetic 
mutation. Consumers may be high risk, with probability Hπ or low risk with probability Lπ  
and 10 <<< HL ππ . The population proportion of high-risk and low-risk types are µ  and 
µ−1 . These parameters are assumed to be common knowledge. 
 
An insurance policy is described by ),( IPC = , where P  is the premium and I  is the 
gross indemnity. The expected utility received by a consumer with probability of loss π  
under the insurance policy C  is 
 
                 )()()1(),( IPlyuPyuCV +−−⋅+−⋅−= πππ . 
 
We let ),( llC tt ⋅= π denote a policy that offers full insurance coverage at an actuarially 
fair rate for a policyholder with loss probability tπ . 
 
 Adverse selection models traditionally assume that individuals are endowed with a prior 
knowledge of their true risk type. That is, it is assumed to be common knowledge that all 
consumers have an informational endowment that includes the individual’s risk type, either 
high or low risk. In this case, the Nash equilibrium consists of a self-selection mechanism in 
which informed consumers are offered their choice from a menu of policies. These policies 
satisfy the self-selection constraints: 
 
     ),(),( HLHH CVCV ππ ≥ , 
     ),(),( LHLL CVCV ππ ≥ . 
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    We let { }′=′ LH CCC ,* denote the menu consisting of the Rothschild/Stiglitz 
equilibrium separating policies. Both of these Policies earn zero expected profit and high 
risk types are fully insured while low types are rationed to less than full 
coverage. ),( lklkC LL ⋅′⋅′⋅=′ π , 10 <′< k . As illustrated by the following figure. 
figure 2: private information, no prevention 
 
 
),(),( * HHHL CVCV ππ =′  
),(),( * LLLL CVCV ππ ′>  
),(),( * LHLL CVCV ππ >′  
Let’s assume that the proportion of the population Uλ , ( 10 ≤≤ Uλ ) has an informed 
endowment that does not include the individual’s risk type. The proportion Hλ  and Lλ  
( 1,0 <≤ LH λλ ) of the population are endowed with the information that they are high and 
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*
HC
LC ′
hy  
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low risk types. Let Hµ  and Lµ  be the proportions of uninformed consumers that are high 
and low risk types; 1,0 << LH µµ  and 1=+ LH µµ . We then have µµλλ =+ HUH , 
µµλλ −=+ 1LUL . All these proportions are assumed to be common knowledge. The 
probability of loss for uninformed consumers is LLHHU µπµππ += . As assumed in section 
2, all the consumers are initially uninformed, then 1=Uλ  and 0== LH λλ  and        
            µµµµ −== 1, LH , LHU πµµππ )1( −+=  
 
 We also assumed that consumers choose to be informed if the value of genetic 
information is at least equal to its cost. As assumed first that the information cost is zero, the 
consumers choose to be informed if the value of genetic information is non-negative. 
 
 Let 0=z  if consumer is uninformed and 1=z  if consumer is informed. As been 
discussed in the benchmark, if all consumers are initially uninformed and choose not to be 
become informed, then there is no informational asymmetry and the market will not exhibit 
adverse selection. The insurer and policyholders share the same estimate of the latter’s 
probability of loss. The premium is perceived by all to be actuarially fair given the absence 
of information and individuals purchase full insurance. A “no information” equilibrium will 
prevail and all policyholders will be fully insured. As shown above, the private value of 
information is negative and the Pareto-optimal policy is ),(* llC UU ⋅= π . 
 
 
3.1.1  The insurer can observe the informational status of the consumers.  
 
  That is, the insurer knows which consumer is uninformed and which is uninformed. 
Then informed consumers will be offered a menu of policies { }LH CC ′,* , with the self-
selection constraints being satisfied: 
 
),(),( * HHHL CVCV ππ =′  
),(),( * LHLL CVCV ππ >′  
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And the uninformed individuals will be offered the contract *UC . Again, the decision to 
become informed is, ex ante, a choice between *UC  with certainty and a lottery over 
*
HC  and 
LC ′ . Since LC ′  yields a lower expected utility than *LC , the value of information in this 
situation is  
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 Risk-averse consumer again prefers *UC  with certainty and the private value of 
information is negative. The intuitive reason for this result is that insurers can write contracts 
that depend on the policyholders’ informational status, offering different policies to the 
informed and uninformed whether or not the test result is observed by the insurer. 
  
 This situation is likely to happen if a not very strict law is enforced concerning the 
insurers’ access to genetic information. Suppose in some countries the test result about a 
specific consumer’s risk type is forbidden to been supplied to the insurer for risk 
classification. But a name list of those accepting the genetic test is available to the insurers. 
In this case, the insurer can determine who are informed and who are uninformed and supply 
the respective contract menu or contract of certainty to the consumers. In this case, we say 
that the informational status is observable to the insurer. And regardless of the information 
cost zero or positive, the value of information is negative. The uninformed will choose not to 
be informed and stay in the state of ignorance of their risk type. 
 
But if in some countries, very strict law forbids the insurer to get access to any 
information about whether consumers accept test or not and the test result, then the 
informational status will be unobservable for the insurer, what will be the value of genetic 
information in this case? 
 
3.1.2 Unobservable informational status 
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    Now we assume that the insurer is unable to observe which policyholders know their 
risk type and which do not, i. e, there is asymmetric possession of the informational status. 
 
   We now assume that insurers expect consumers to become informed. If there is 
equilibrium then it is at the contract { }LH CCC ′= ,* , uninformed policyholders would 
purchase the low-risk policy because as illustrated by figure 3, it offers higher utility for the 
uninformed than the policy for the high-risk individuals.  The value of information is  
 
     ),(),()1(),( * ULLLHH CVCVCVVI ππµπµ ′−′−+⋅=  
 
      Because the contract LC ′  has the same value as *HC  for the high-risk consumers, 
),(),( * HHHL CVCV ππ =′ , and because the expected utility property given by Hal R. Varian 
in “Microeconomics Analysis”: )()1()())1(( yuxuyxu ⋅−+⋅=−⊕ µµµµ oo , 
which means that the utility of a lottery is the expectation of the utility from its prizes.  
Then the value of information can be transformed into 
 
        ),(),()1(),( ULLLHL CVCVCVVI ππµπµ ′−′−+′⋅=  
Q   LHU πµµππ )1( −+= ,   
∴   
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    The value of information is zero and according to our assumption before, the 
uninformed will choose to become informed. Of course this is a very weak dominant 
strategy. 
 
Next we will consider the case in which insurers expect consumers to remain uninformed. 
 
 Suppose there is equilibrium at the policy set { }LUH CCCC ′′′′′′=′′ ,, . These policies satisfy 
the zero expected profit conditions and the self-selection constraints: 
 
           ),(),( HLHH CVCV ππ ′′>′′ , 
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           ),(),( HUHH CVCV ππ ′′=′′ , 
           ),(),( HLUU CVCV ππ ′′=′′ , 
           ),(),( UHUU CVCV ππ ′′>′′ , 
           ),(),( LHLL CVCV ππ ′′>′′ , 
           ),(),( LULL CVCV ππ ′′>′′ . 
 
Where the policy HC ′′ is the same as *HC that offers full coverage for the high risks. And 
UC ′′ offers the same utility as HC ′′  for the high risks but less utility than the full coverage 
policy *UC for the uninformed individuals. The policy LC ′′  offers the same utility as UC ′′ for the 
uninformed ones but less utility than the full coverage policy *LC for the low-risk individuals. 
The policy set is illustrated by the following figure:  
 
figure 3: no prevention, unobservable information status 
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Now the value of information is  
 
              ),(),()1(),( UULLHHHH CVCVCVIV ππµπµ ′′−′′−+′′⋅=′′  
 
Because  ),(),( ULUU CVCV ππ ′′=′′  and adding and subtracting ),( HLH CV πµ ′′⋅  yields  
 
              { }),(),( HLHHH CVCVIV ππµ ′′−′′=′′         
                   { }),(),()1(),( ULLLHHLH CVCVCV ππµπµ ′′−′′−+′′+  
 
Since LHHHU πµπµπ )1( −+= , the second term is zero, We can get  
 
                 { } 0),(),( >′′−′′=′′ HLHHH CVCVIV ππµ , 
 
 because the policy HC ′′ is preferred by the high-risk individuals to LC ′′ . 
 
Thus, uninformed policyholders would choose to become informed. But after being 
informed, the consumer will buy a policy *HC  if revealed to be a high-risk one and a policy 
LC ′  if revealed to be a low-risk one. The equilibrium will be the policy set ),( * LH CCC ′=′ . 
So there can not be an equilibrium when insurers expect consumers to be uninformed. 
 
3.1.3 Unreported bad risks and verifiable good risks 
 
We now consider the case in which the consumer has an incentive to report favorable 
results and conceal unfavorable results. Imagine a genetic test for Huntington’s disease. 
Those who take the test and receive a negative result report that result to the insurer and 
receive a policy priced according to the favorable result. Those who take the test and receive 
a positive result clearly have an incentive to conceal their having taken the test. This 
asymmetric reporting may be reinforced by a “consent law” which requires that consumers 
give their consent before test results can be revealed to third parties. Thus, the insurer cannot 
differentiate between those who are uninformed and those who have been tested positive. 
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In this case we first assume that insurers expect consumers to become informed. Those 
been tested negative (low-risk types) will report the test result to the insurer and will receive 
*
LC , all others are offered 
*
HC , these are both the full coverage policies. The value of 
information then will be: 
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    0)),(),()(1( ** >−−= LHLLH CVCV ππµ , 
 
because the policy *LC  is preferred by the low risks to 
*
HC . 
 
Second assume that the insurers expect consumers to remain uninformed. It will still offer 
*
LC  to those been tested negative. However, since the insurer cannot distinguish between the 
uninformed and those concealing positive test results, the insurer offers a submenu of 
contracts )(* HH CC ′′=  and UC ′′  to those not reporting the test results. Since this submenu 
satisfies the self-selection constraints: 
 
            ),(),( HUHH CVCV ππ ′′=′′  
            ),(),( UHUU CVCV ππ ′′>′′  
 
The informed with positive results will select *HC  and the truly uninformed will choose 
UC ′′ . The set of contracts is { }**** ,, LUH CCCC ′′= . The value of information is then: 
 
         ),(),()1(),( **** UULLHHHH CVCVCVVI ππµπµ ′′−−+=  
                [ ]),(),()1( ),(),()1(),( * LULLH UULUHHUH CVCV
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The term in the first braces disappears and the value of information is 
 
           [ ] 0),(),()1( *** >′′−−= LULLH CVCVVI ππµ  
 
 The value of information is positive and the uninformed policyholders will choose to 
become informed.  
 
Proposition: Assume that consumers can choose to observe their risk type at zero cost, 
informed and uninformed consumers cannot be distinguished, and risk type is not directly 
observed by insurers. We assume that consumers can choose whether or not to report 
verifiable test results and that this is the only information on risk type available to the 
insurer. Then in this case the information has positive value for the uninformed consumers 
and they choose to be informed. 
 
Compare this with the situation under which the insurers can observe information status, 
this result is quite easy to explain. When information status is fully observable, the insurer 
can offer *HC , 
*
UC , 
*
LC  respectively to the informed high-risk types, the uninformed and the 
informed low-risk types. The value of information to the uninformed is negative and they 
would never choose to become informed. This result contrasts with the positive value 
obtained when consumers can choose to reveal or conceal information status. Because they 
can always get a better contract of *LC  if revealed to be a low-risk one and remain to accept 
the contract UC ′′  or *HC  with the same utility for them if revealed to be a high-risk one and 
conceal this result. So the test will supply more choice for them and make them better off. 
 
 
 
 
3.1.4 Information costs 
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    To this point we have assumed information could be acquired costlessly. We now 
introduce explicit information costs r  and assume that utility is separable in information 
costs. 
 
If the contract is C ′′ , then the value of information is 0>′′IV , as shown before. If 
rIV <′′ , then the net value of information is negative for uninformed policy-holders. These 
individuals choose not to learn their risk type and the equilibrium contract set is C ′′  with 
*
HC  for the informed high risks and UC ′′  for the uninformed and LC ′′  for the uninformed low 
risks.  If rIV >′′  then the net value of information is non-negative and the uninformed 
policyholders choose to be informed and then C ′′  cannot be an equilibrium. Because the 
high risks and those revealed high risks from the uninformed will buy the contract *HC . 
Those originally informed to be low risks and revealed to be low risks from the uninformed 
will buy the contract LC ′′ .  
 
And then can C′  be an  equilibrium? At C′  the value of information is rIV <=′ 0  and 
uninformed policyholders choose not to learn their risk type. Moreover, the uninformed 
policyholders will still choose LC′  over *HC  from the menu of policies. But then LC′  is a 
pooling policy for policyholders with loss probability Lπ  and Uπ . And it follows that C′   
cannot be an equilibrium contract. So if rIV >′′ , then no equilibrium exists. 
 
3.2 Prevention available  
 
When information is private and prevention is available, the choice of the uninformed 
consumers to be tested or not has been well studied in Hoel and Iversen (2002). They 
assume that there is a mix of compulsory and voluntary insurance available. 
 
In this part we will first show some results similar to those given by Hoel and Iversen and 
then consider the impact of information cost on consumers’ choice about whether to accept a 
test or not. 
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We assume that the prevention an individual undertakes is his private information. Also 
the cost of prevention is private information. Hence, an insurance contract cannot be made 
contingent on whether prevention is undertaken. We also impose the institutional constraint 
that insurers have no access to information about whether a person is tested. Since those 
tested then cannot be distinguished from those not been tested, insurance contracts can 
neither be contingent on whether a person is tested nor on the test result. 
 
For simplicity, we assume that the prevention cost v  is a fixed number but not a 
continuous variable chosen at an optimal level by those tested to be high risks. And the 
prevention can reduce the loss probability of the high risks from Hπ  to Hs π⋅ , while it 
cannot make the illness risk as low as it’s for the low-risk consumers. So  01 >>⋅> LHs ππ . 
We still assume no compulsory insurance as before and all consumers initially have the same 
perception of risk type as the weighted average of two risk types: 
  LHU πµµππ )1( −+= . 
 
As illustrated by the figure, contract *HSC  will be available for those been tested positive 
and take prevention. The net utility after prevention is greater than the utility of taking no 
prevention and purchasing the insurance of full coverage. 
 
Case 1: consumers can reveal the negative results (low risk) and conceal the positive 
result (high risk). But the prevention is socially efficient for the high-risk persons.  
 
By taking preventive measures, the endowment point A  moves to A′  because of 
preventive cost in both states. And the slope of the budget line also changes due to the effect 
of the prevention on loss probability. Full insurance policy *HSC  will be offered to those 
people who have taken prevention after being tested positive. 
 
 If a person remains uninformed, he will be offered a contract UC′  with the self-selection 
constraints satisfied: 
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figure 4: prevention available, private information 
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Those who reveal negative results to insurer will receive the policy *LC  with full coverage 
and low price. But those do not reveal the result will be viewed as uninformed and be 
offered the policy set { }UHS CC ′,* , so the value of information in this case is  
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 ),(),()1(),( **1 UULLHSHS CVCVCVVI ππµπµ ′−−+=  
       ),(),()1(),( ** UULLHH CVCVCV ππµπµ ′−−+>  
       
0
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=
′−′−+′> UULUHU CVCVCV ππµπµ  
                     
 
So the value of information is positive and the uninformed will accept the test. After 
testing, they will reveal the negative result to the insurer and take prevention if the result is 
positive. 
 
The intuitive reason is obvious: the uninformed can always be better off by revealing the 
negative result and receiving a cheaper policy at full coverage. While he will have the same 
utility by taking prevention and buy a policy *HSC  if revealed to be a high-risk one. So the 
total value of the genetic information is always positive and the equilibrium policy set is 
{ }** , LHS CCC =′ . 
 
But the above conclusion comes from the assumption of costless information. If there is a 
cost of information r  and 1VIr > , the net value of information is negative. The consumers 
will remain uninformed. In this case, all consumers will accept the uniform policy UC′  and 
there is a highly signaling cost for the low-risk ones. 
 
Case 2: the information status unobservable 
 
In this case the insurer can not judge which one is informed or uninformed of the risk 
type. So they offer a contract set { }LUHS CCCC ′′′=′′ ,,*  for the consumers. These policies earn 
zero expected profit and satisfy the self-selection constraints: 
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            ),(),( ULUU CVCV ππ ′′=′  
            ),(),( LULL CVCV ππ ′>′′  
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            ),(),( * HSHSHSL CVCV ππ <′′  
 
then the value of information is  
 
              ),(),()1(),( *2 UULLHSHS CVCVCVI ππµπµ ′−′′−+=  
                  ),(),()1(),( * UULLHH CVCVCV ππµπµ ′−′′−+>  
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So the value of information is positive and the uninformed will choose to be tested. If 
compared with the result got under the situation of private information and no prevention 
avialable, this result is quite reasonable. Because in the situation of no prevention, the value 
of genetic information is positive. Now with the prevention being available and socially 
efficient for the high-risk individual, it is even more valuable for the uninformed to choose 
to be tested and take prevention if revealed to be high risks afterwards. So in the situation of 
private information and prevention available and socially efficient for the high risks, the 
vlaue of genetic information is positive and the uninformed will choose to be tested and take 
prevention if revealed to be high risks. 
 
 This is consistent with the situation given by Hoel and Iversen(2002) when there is no 
compulsory insurance. In their analysis, it is assumed that compulsory insurance covers a 
portion lx ≤  of the loss.  It is exogenous and equal for all. Voluntary insurance covers loss 
in excess of x . And it is assumed that for a person who can buy unlimited supplementary 
insurance at an actuarially fair price and who does not know whether he is high risk or low 
risk, it is not worthwhile to undertake prevention. Formalization of this assumption is that 
lsv H ⋅⋅−> πµ)1( . 
 
The left-hand side is the cost of preventive measures, while the right-hand side is the 
reduction a fully insured uninformed person gets in the actuarially fair insurance premium as 
a consequence of the preventive measures he undertakes. 
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Due to this assumption, it is ruled out of the choice of undertaking prevention without 
test. And the choice of test without prevention if revealed to be high risk is also ruled out 
because of the assumption that prevention is socially efficient for high-risk persons. Stated 
formally, it means: 
           lsv H ⋅−< π)1(  
 
The left-hand side is the cost of prevention and it’s lower than the increase in expected 
income due to prevention for a person who is high risk. 
 
Then the condition for an uninformed individual to choose to be tested and take 
prevention if revealed to be high risk is as follows: 
        )()1( xlsv H −−< π  . 
 
  So here it is clear that the higher proportion of compulsory insurance, the less likely an 
individual will choose to be tested. In our analysis, 0=x  and it is assumed to have no 
compulsory insurance. The result is the same that the consumers will choose to be tested 
since the value of information is positive for them. 
 
To encourage a person with mixed compulsory and voluntary insurance to undertake 
testing and prevention, a kind of genetic insurance is highly recommended. It is suggested 
that the government should offer insurance against the cost of being identified as a high-risk 
person. Since the costs of being identified as a high-risk person compared to a low risk 
person is vxls LH +−− ))(( ππ , actuarially fair insurance can be offered at the cost 
[ ]vxls LH +−− ))(( ππµ . With fair insurance against the loss of being identified as high risk, 
an uninformed person will choose the testing and prevention option since this option now 
offers the highest expected income and utility. 
 
 This is also stated by Tabarrok(1994). He argues that the potentially negative effects of 
predictive testing on insurance coverage and income distribution could be avoided by 
introducing compulsory insurance against the financial consequence of becoming high risk 
when a person decides to be tested.  
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 So according to the analysis above, we can put forward the following proposition: When 
there is prevention available and it being socially efficient for the high-risk individual, the 
value of genetic information is positive and the uninformed will choose the test and take 
prevention if revealed to be high risk. This applies especially to the case of no compulsory 
insurance. With a high proportion of compulsory insurance the uninformed will less likely to 
be tested. To encourage the test and prevention to be undertaken,  a kind of new genetic 
insurance can be enforced by the government to avoid the economic loss of being identified 
as a high-risk individual. 
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4. Social efficiency and policy implications 
 
4.1 The social value of genetic information  
 
    Till now we have considered the private value of genetic information. There is another 
important aspect of genetic information: the social value. There is no explicit definition for 
social value of genetic information but it is always put forward relative to the notation of 
private value. The latter is the benefit genetic testing brings to individual by increase of 
income due to less premium or better insurance policy with high utility. The former is the 
total effect of genetic testing to not only the individual being tested but also the other people 
affected. In this paper, we don’t take into account the externality of genetic information due 
to altruism. This includes the pleasure felt by the family or friends when one is found to be 
low risk by taking a genetic test. We only consider the economic value of genetic 
information for the society. 
 
Milgrom and Stokey(1982) have shown that if parties negotiate ex ante efficient contracts 
in a complete market, then subsequently generated information that does not create new 
investment opportunities has zero social value. By way of illustration, consider a person who 
takes a diagnostic test for Huntington’s disease. Since there is little effective treatment, we 
can assume that the allocation set is not expanded by the test. But the information generated 
by the test can be used to redistribute income through life and health insurance. From 
Milgrom and Stokey we conclude that these insurance opportunities have zero social value. 
  
 Crocker and Snow’s(1992) show that, if agents initially have no private information, then 
the Pareto-optimal contracts involve no signaling. It is the case of public information and 
actuarially fair insurance offered to each risk type. When individuals initially possess hidden 
information, additional hidden information brings social benefits since it permits agents to 
sort more finely. However, additional hidden information also increases the costs to some 
agents of signaling their risk type. It is respectively the case for high risks and for low risks. 
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On balance, the social value of information can be positive or negative depending on which 
effects dominates. 
 
     Doherty and Thistle(1996) analyze the case where insurers cannot observe whether 
consumers have obtained a test. They show that, in this context, acquiring information 
always has a positive private value. Since by taking the test the market possibilities 
(especially the price of insurance) do not change for the individual but better information 
allows consumers to make a more informed choice, that is, to adjust the amount of insurance 
they buy to what is optimal for their risk type. However, the social value of the testing 
opportunity is negative. If there were no asymmetric information before the test, all 
individuals would insure for a medium premium. If insurers could observe test results then, 
depending on the outcome of the test, some (those with good news) could buy insurance 
cheaper and for those with bad news, the premium would increase. By the martingale 
property of conditional expectation, the expected premium could be the same as the medium 
premium before. But since the premium is a random variable and individuals are risk averse, 
all are worse off from an ex ante perspective. Asymmetric information after the test 
aggravates this problem, since low risks cannot buy full insurance for the low premium but 
must signal their risk type by purchasing only partial coverage. 
     
 In Hoy and Polborn(2000), different results from above have been derived. They assume 
that the insurance demand change with the loss probability. The higher probability of getting 
ill, the more insurance coverage will be demanded when there is no premium risk. Knowing 
one’s risk type allows one to make a more informed choice about the optimal level of 
insurance coverage. This is the case for health insurance market. Only people with high risk 
of disease will always buy a lot of insurance. However, when a sufficiently large number of 
individuals become better informed about their risk types, there will be market price effects 
as changes in demand by different risk types will lead to changes in the average cost of 
providing insurance. 
 
 They assume that in the reference situation only high risks buy life insurance. This is 
possible since the premium might be unacceptably high for low risks and uninformed 
individuals. Hence the premium will be based on the high risks’ probability of illness. After 
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the genetic testing, the high- risk part of the uninformed will buy insurance. Therefore, the 
ex ante expected utility for uninformed consumers is increased by the testing opportunity. 
   
  Besides there being a possible positive value of insurance for those who take the test, 
there is also the possibility of positive price spillover effects for those who don’t take the 
test. Suppose there is a range of risk types so that an uninformed individual who take the test 
may be determined to be one of a number of higher or lower risk types. If such a person 
initially does not buy insurance and upon testing discovers he is of a high- risk type but that 
he carries a risk level less than the average of those who initially purchase insurance. After 
his buying insurance the result will be a lower equilibrium price of insurance which will be 
to the advantage of the original pool of insurance buyers. Negative price spillover effects are 
also possible if he is discovered to be a risk type higher than the average risk of those 
originally purchasing insurance. 
    
  So the total effect of genetic testing on the social efficiency can be positive, negative or 
zero. It depends on the sum of positive value of insurance purchasing by those initially 
uninformed and the price spillover effects afterwards. 
   
  In Hoel and Iversen(2002) it is defined as socially efficient for genetic testing if the cost 
of prevention is less than the increased income due to cheaper insurance by taking 
prevention for a high risk individual. They also show that when information about 
prevention and test status is private, two types of social inefficiencies may occur. Genetic 
testing may not be done when it is socially efficient and it may be done although it is 
socially inefficient. The first type of inefficiency is more likely for those who have 
supplemented the compulsory insurance with substantial voluntary insurance. The second 
type of inefficiency is more important the less effective prevention is.  
 
   Yet the genetic therapy is likely to lag behind the development of genetic diagnostics. 
And hence, the scope for effective prevention is also limited. In the present years it is 
possible that genetic testing is expensive and effective prevention unavailable. So the 
problem of genetic testing is not so serious. But with the development of technology, much 
cheaper testing will be available and preventive measures will be discovered by and by. The 
question will arise that whether some institutions such as the insurance company and 
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employers should use the genetic information for underwriting?  In the next part of this 
section, we will introduce some policies concerning the access of insurers to the genetic 
information. 
 
4.2 Policy implications 
 
There are different attitudes about whether insurers should get access to the genetic 
information and make use of it for risk classification. A number of national and international 
committees and advisory groups have developed and published recommendations for policy 
makers to protect individuals against genetic discrimination. Three solutions are usually 
proposed: 1) prohibition of any use of genetic information; 2) legislation prohibiting this 
below a certain amount of coverage; and 3) moratoria.  
 
    The approaches used in different countries vary greatly. In five European countries: 
Austria, Belgium, Denmark, France and Norway, any use of genetic information for business 
purposes is prohibited. In four countries, France, Germany, Sweden, and the United 
Kingdom, a moratorium or partial moratorium on the use of genetic information by insurers 
has been established. In the Netherlands, the Medical Examination Act (1998) prevents the 
acquisition of genetic information by insurers and employers below a certain amount of 
coverage. At the European level, the Council of Europe signed a convention for the 
Protection of   Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine in 1997. The same year, the UNESCO Universal 
Declaration on the Human Genome and Human Rights was signed. In the United Kingdom, 
there is a human Genetics commission addressing these policy issues, with specific 
committees in which consumers, business groups, geneticists and other stakeholders, work 
together to advise Government of developments and options. In the US, a majority of the 
states have banned the use of genetic information by insurers. The Congress in 1996 passed 
legislation that forbids group health organizations from denying coverage on the basis of 
genetic information.  Effects are also being made to extend the prohibitions to all health 
insurers and to ban insurers from raising premiums based on genetic data. Recently 
(February 2001), a bill to prohibit discrimination on the basis of genetic information with 
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respect to health insurance was introduced in the US senate and referred to the committee on 
Health, Education, Labor and Pensions. 
 
  Despite the desire to restrict the use of genetic information for non-medical purposes, a 
balance appears necessary between the economic interests of insurers and employers, the 
interests of applicants and the interests of other policyholders and other employers. This is 
especially relevant and sensitive under health care systems and welfare sectors with 
increasing budgetary restrictions. 
 
  In the insurance market, adverse selection is a classical problem. It occurs when people 
have undergone testing and conceal positive results from insurers. Insurers require symmetry 
of information. If the insured person does not disclose information which the insurer needs 
to know, then this disrupts the equilibrium of the relationship and the possibility of adverse 
selection arises. If insurers are prohibited from having access to pertinent information at the 
time if underwriting or when the policy is renewed, the applicants could use genetic 
information to abuse the insurance system, taking advantage of private knowledge of the 
risks they submitting for coverage. The consequences of a lack of symmetry in information 
between insurers and applicants or insured persons could force insurers to adjust premiums. 
In the Netherlands, after the Medical Examination Act has been in force, insurers have taken 
measures to prevent the risk of adverse selection by implementing premium increases in 
advance. By prescribing a maximization of the pension pay out or basing payments on a 
maximum salary, or by including an option to increase the premium in the policy. Dutch 
insurers have also introduced waiting time for existing illness when issuing the insurance. 
This means that if, within a term stipulated in the waiting time, the insured becomes disabled 
or dies as a result of an illness that he had when he took out the insurance, no payment will 
be made. As in our analysis before, when the informational status is asymmetric, the value of 
information is always positive and people will choose to undertake testing. This will induce 
insurers to take the above mentioned measures to avert the problem of adverse selection. But 
then there is great signaling cost for the low-risk individuals. Except in the situation that 
they can reveal negative results to the insurers, they will suffer a high premium or not full 
coverage due to the problem of adverse selection. As the enforcement of prohibitive laws in 
many countries, this problem will be aggravated. 
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 There are several ways to alleviate this consequence as the prohibitive laws become 
more and more general in many countries.   
 
1. A compulsory insurance can be implemented to cover partial loss of illness. As 
analyzed by Hoel and Iversen, the higher the proportion of compulsory insurance, the 
less likely the uninformed would choose to be tested and the less seriousness of the 
problem of adverse selection. A proper amount of compulsory insurance will make the 
high risks and the low risks both better off. The bad risks profit from the subsidization 
by the good risks while the good risks pay a little more that fair premium for a basic 
protection from insurance. 
 
2. Advance of technology: with the development of technology, more and more effective 
measures will be found to prevent genetic diseases and decrease the probability of 
getting ill. Then the high-risk people can protect themselves by taking prevention 
instead of purchasing large amount of insurance. This prospect is not so dreaming 
since technology has always been developed rapidly. So the governments can invest 
even more on bio-technology to find more effective prevention or treatment for 
genetic diseases. This is to the benefit of all the human beings. 
 
3. Consent-law: With the consent law the genetic information will be used by the 
insurers after the approval of insureds. This can at least make the low risks better off 
without threat to the benefits of other people. By revealing to be low risks, this group 
if people can get a cheaper and full insurance coverage. And as our analysis before, 
the high risks can be of the same well being by taking prevention and purchasing 
insurance policy at full coverage. 
 
4. Genetic insurance: As highly recommended by a lot of researchers genetic insurance is 
really a new possibility for the solution of the problem generated by genetic testing. 
By a compulsory insurance against the probability of being identified as high risk, the 
high risks can get rid of the fear of financial loss from positive results. And the test 
results can then be used by the insurers for a more finely risk classification. The 
problem of adverse selection will not arise then. But there are still problems with this 
suggestion. First, many genetic diseases are multi-factorial. The disease occurs 
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because of not only abnormal genetic mutation but also other reasons such as the 
environment, the life habit and each individual’s susceptibility. Then the exact 
influence of genetic disorder is hard to be estimated. And then the price of genetic 
insurance is hard to be specified. Second, there will also be the problem of adverse 
selection here. Those perceiving to be low risk would not like to undertake test and on 
the other hand, those perceiving to be high risk would like to be tested. Then the price 
of genetic insurance may be prohibitively high for it to be accepted by everyone. After 
all, it is a good suggestion to solve the problem of adverse selection after genetic 
testing.  
   
  Of course the application of these suggestions is a little far from the reality. Further 
research needs to be done with respect to the concrete details of policy implementation.  
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5. Concluding remarks 
 
As analyzed in the previous sections, the existence of private information makes it always 
attractive to accept the genetic test for the uninformed individuals. And there is an incentive 
for high risks to conceal the results. This has a negative externality on the low risks while 
the high risks are not better off from the loss of the low risks. 
 
 So it seems preferable that genetic information should be shared by both the insureds and 
insurers. As stated in the Economist (2000), the government have a role to play in 
compensating the unfortunate in the lottery of the gene pool. 
 
 But there are different opinions regarding the importance of the issues that this paper has 
raised.  
 
 First, Watts (1999) and Bonn (2000), refer to geneticists who argue that the fears of the 
impact of genetic testing on insurance are unfounded. The predictive power of genetics is 
said to be exaggerated. Although there are some useful predictive genetic factors for multi-
factorial diseases, the associated risks are said to be too difficult to assess for underwriting 
purposes.  
 
 Second, genetic testing by health insurers primarily affects the market for individual 
policies. Group insurance and individual insurance are fundamentally different products, and 
their underwriting practices differ substantially. Medical underwriting is limited generally to 
the individual and small-group insurance market. Large-group insureds, on the other hand, 
are issued policies without direct considerations of the insurability of individual members of 
the group. If a high proportion of the population (say, 90%) is covered by group policies, is 
there significance of studying the impact of genetic testing on insurance market? 
 
     Third, raising insurance rates because of abnormal genetic tests is problematic because 
individuals are penalized for traits over which they have no control. Often, insurance rates 
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are raised to encourage responsible behavior. Thus, for example, smokers pay higher rates 
for nonsmokers; individuals with high cholesterol levels may also pay higher rates. In these 
cases, there is a genetic component to the high risk, but there is also an element of personal 
responsibility, and the higher rates are designed to influence personal behavior. With genetic 
tests, however, there is nothing the individual can do to affect the outcome. So if this 
argument justifies, there should be policy restricting insurers raising insurance rates due to 
people’s genetic test revealing positive results. And then our analysis should consider this 
restriction then. 
 
  There are also some assumptions of our models need to be modified and explored in 
future research. 
 
  We have assumed that all consumers have the same perception of their risks prior to 
genetic testing. But this is not quite realistic. For instance, family history may be used to 
distinguish between high- and low- risk individuals. An important modification is then to 
allow for consumers to have some ex ante information of their risk type. 
 
 We assumed no preference for good health. The motivation for good health was confined 
to preference for income. The consequence of including health as a separate argument in the 
utility function should be explored in future work. Hence, the introduction of state dependent 
utility function, as in Strohmenger and Wambach (2000), will be an analytic tool in future 
work. 
 
  Finally, we assumed no compulsory insurance throughout. But in reality, a compulsory 
insurance is always supplied to maintain a basic need for insurance in many countries. So the 
introduction of a mix of compulsory and voluntary insurance is necessary for future 
research. 
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